

Supporting Information for

ORIGINAL ARTICLE

Escape from abluminal LRP1-mediated clearance for boosted nanoparticle brain delivery and brain metastasis treatment

Naveed Ullah Khan^a, Jiang Ni^{a,b}, Xiufeng Ju^a, Tongtong Miao^a, Haiyan Chen^a, Liang Han^{a,*}

^a*Jiangsu Key Laboratory of Neuropsychiatric Diseases Research and College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China*

^b*Department of Pharmacy, Affiliated Hospital of Jiangnan University, Wuxi 214000, China*

Received 11 July 2020; received in revised form 14 September 2020; accepted 23 September 2020

*Corresponding authors. Tel./fax: +86 512 65882089.

E-mail address: hanliang@suda.edu.cn (Liang Han).

Running title: Escape from abluminal LRP1-mediated clearance for boosted brain targeting




Figure S1 The polydispersity indices for the hydrodynamic size of DOX-loaded NPs and LAP-loaded NPs by dynamic light scattering. Data are presented as mean \pm SD ($n=3$).




Figure S2 The loading efficiency of DOX and LAP in various NPs. Data are presented as mean \pm SD ($n=3$).




Figure S3 In vitro uptake of IR780-loaded NPs-K-s-A in bEnd.3 cells. The uptake parameter was set at 1.8 µg IR780/mL for 2 h. The NPs were pre-incubated with MMP1 (7.8 ng/mL) for different time with different concentration specific MMP1 inhibitor FN439. Data are presented as mean ± SD ($n=4$). *** $P < 0.001$.




Figure S4 In vitro uptake of IR780-loaded NPs-K-s-A and NPs-K-i-A in bEnd.3 cells. The uptake parameter was set at 1.8 µg IR780/mL for 2 h. The NPs were pre-incubated with MMP1 (7.8 ng/mL) for 2 h with or without 1 µmol/L FN439. Data are presented as mean ± SD ($n = 4$). *** $P < 0.001$.




Figure S5 Representative image of LRP1 expression determined by Western blotting on bEND.3 cells, which were treated with DMEM, or MDA-MB-231Br-HER2 conditioned medium (MCM) for 24 h. 231Br cells were used as control.




Figure S6 The distribution percentage of DOX-loaded NPs-K-i-A and NPs-K-s-A in blood side, brain endothelium and brain side on an in vitro BBB model. Amounts of DOX were measured after 6 h incubation in DMEM or MCM. Data are presented as mean \pm SD ($n=3$).




Figure S7 Quantitative biodistribution (% ID/g) of intravenously injected various IR780-loaded NPs (0.75 mg IR780/kg) in normal mice. Data are presented as mean \pm SD ($n=5$).




Figure S8 Quantitative biodistribution (% ID/g) of intravenously injected various IR780-loaded NPs (0.75 mg IR780/kg) in BCBM-bearing mice. Data are presented as mean \pm SD ($n=6$).




Figure S9 Representative bioluminescence images of chosen mice for *in vivo* antitumor evaluation. Bioluminescence imaging was performed by IVIS imaging system on Day 1 after intracardiac injection to screen successful animal models.